絞り込み

16546

広告

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

著者 Kearsley-Fleet L , Davies R , De Cock D , Watson KD , Lunt M , Buch MH , Isaacs JD , Hyrich KL ,
Ann Rheum Dis.2018 Jul 06 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (10view , 0users)

Full Text Sources

Biologic disease-modifying antirheumatic drugs (bDMARDs) have revolutionised treatment and outcomes for rheumatoid arthritis (RA). The expanding repertoire allows the option of switching bDMARD if current treatment is not effective. For some patients, even after switching, disease control remains elusive. This analysis aims to quantify the frequency of, and identify factors associated with, bDMARD refractory disease.
PMID: 29980575 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード